Idiopathic Pulmonary Fibrosis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

MARKET OUTLOOK

Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. It is characterized by an irreversible loss of lung function, leading to high morbidity and mortality; most patients die within three to five years following diagnosis. Pirfenidone (Roche’s Esbriet) and nintedanib (Boehringer Ingelheim’s Ofev) are the only two drugs approved to treat adults with IPF. In addition to these two disease-modifying therapies (DMTs), physicians prescribe off-label medications (e.g., corticosteroids, anticoagulants) to IPF patients when the risk/benefit profile does not warrant treatment with pirfenidone or nintedanib or when patients cannot access these DMTs. Our Treatment Algorithms study provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated IPF patients, providing insight into the current treatment landscape for this indication.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed IPF patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed IPF patients?
  • How has pirfenidone been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of IPF patients receive drug therapy within a year of diagnosis and how quickly? What percentage of patients progress to later lines of therapy within a year of diagnosis?
  • What percentage of IPF patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

SOLUTION ENHANCEMENT

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.

Markets covered: United States

Key companies: Novartis, Genentech, Viatris

Key drugs: Pirfenidone, imatinib, Revatio, nintedanib

Table of contents

  • Idiopathic Pulmonary Fibrosis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
    • Treatment Algorithms CDA Idiopathic Pulmonary Fibrosis US April 2021
    • Treatment Algorithms CDA Idiopathic Pulmonary Fibrosis US 2021 Dashboard